What serologic markers (antineuclear antibody (ANA), smooth muscle antibody (SMA), anti‑liver‑kidney microsomal type 1 (anti‑LKM‑1), anti‑soluble liver antigen/liver‑pancreas antigen (anti‑SLA/LP), perinuclear antineutrophil cytoplasmic antibody (p‑ANCA), elevated immunoglobulin G (IgG)) are used to diagnose autoimmune cirrhosis?

Serologic Markers for Autoimmune Cirrhosis (Autoimmune Hepatitis)

The essential serologic markers for diagnosing autoimmune hepatitis (AIH) are antinuclear antibodies (ANA), smooth muscle antibodies (SMA), anti-liver-kidney microsomal type 1 (anti-LKM1), anti-liver cytosol type 1 (anti-LC1), anti-soluble liver antigen/liver-pancreas antigen (anti-SLA/LP), and elevated immunoglobulin G (IgG), with first-line screening performed by immunofluorescence testing on triple rodent tissue sections at dilutions of 1:40 in adults. 1

Primary Diagnostic Algorithm

The 2025 EASL guidelines provide a clear hierarchical approach to autoantibody testing 1:

First-Line Screening

• ANA, SMA, anti-LKM1, and anti-LC1 should be tested by immunofluorescence (IFT) on fresh frozen liver, kidney, and stomach rat tissue sections
• Anti-SLA/LP should be tested simultaneously using solid phase assays (ELISA)
• Initial dilution: 1:40 in adults, 1:10 in children
• If negative at standard dilution, retest at lower dilution (1:40) before declaring negative 1

Autoantibody Patterns Define AIH Subtypes

Type 1 AIH (AIH-1):

• ANA and/or SMA positive
• Most common presentation (approximately 85-95% of cases)
• May also have anti-SLA/LP positivity 1, 2

Type 2 AIH (AIH-2):

• Anti-LKM1 and/or anti-LC1 positive
• Less common, typically in children
• Anti-SLA/LP can also be present 1, 2

Immunoglobulin G Elevation

85-95% of AIH patients have elevated IgG levels, even without cirrhosis 1. However, critical caveats exist:

• Only 25-39% of acute presentations have elevated IgG at diagnosis
• Normal IgG does not exclude AIH
• Patients with normal IgG at diagnosis have better long-term remission rates after treatment withdrawal 1

Scoring System Integration

The simplified AIH score incorporates these markers 1:

Autoantibody Points:

• ANA or SMA >1:80 OR anti-LKM >1:40 OR anti-SLA/LP positive = 2 points
• ANA or SMA >1:40 = 1 point

IgG Points:

• 1.1x upper limit of normal (ULN) = 2 points

• ULN = 1 point

Score interpretation: >6 = probable AIH; >7 = definite AIH

Additional Markers

Perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA):

• Present in approximately 39% of AIH-1 patients 3
• Not specific for AIH - also seen in primary sclerosing cholangitis
• Should be tested if standard antibodies are negative but clinical suspicion remains high 1

Critical Diagnostic Pitfalls

Seronegative AIH

Approximately 10-20% of AIH cases are seronegative despite typical clinical and histological features 4. When standard testing is negative:

1. Repeat testing at reference laboratories for both standard and non-standard antibodies (anti-dsDNA, anti-F-actin, anti-Ro52, anti-α-actinin) 1
2. If expert testing remains negative but clinical suspicion persists, liver biopsy is mandatory 1
3. Seronegative AIH has 11.7 times higher risk for transplantation or death 5

Technical Considerations

• Anti-LKM1 is frequently confused with anti-mitochondrial antibody (AMA) if only kidney substrate is used - this is why triple tissue sections are essential 2, 6
• HEp-2 cells can be used for ANA/SMA but require higher dilution cutoffs (1:80 or 1:160) 1
• Anti-SLA/LP is 100% specific for autoimmune liver disease when present, but only detected in 14% of AIH patients 7

Overlap Syndromes

When cholestatic features are present:

• Test for PBC-specific antibodies (AMA-M2, anti-gp210, anti-sp100) before other investigations 1
• Consider magnetic resonance cholangiography for PSC, especially in children and young adults with cholestasis 1
• In children, all cases should have cholangiography regardless of cholestatic enzyme elevation due to high prevalence of autoimmune sclerosing cholangitis 1

Laboratory Quality Requirements

All clinical laboratories must adhere to guideline-specified cutoffs and techniques 1:

• Use IFT on triple rodent tissue sections as gold standard
• Report at appropriate dilutions (not higher than 1:40 initial screening in adults)
• Offer anti-SLA/LP testing by validated solid phase assays
• Maintain quality assurance programs for autoantibody detection 6

The presence of autoantibodies alone cannot establish definitive diagnosis - liver biopsy remains mandatory to confirm AIH diagnosis, grade activity, and stage fibrosis 1.